Based on the encouraging anti-tumor efficacy and favorable safety profiles, a pivotal phase 2 study has been initiated to further assess the efficacy and safety of SY-5007 at RP2D (160 mg BID) in patients with locally advanced or metastatic RET fusion-positive NSCLC (NCT05278364). The gene discussed is RET; the disease is neoplasm.